Citalopram in patients with fibromyalgia - a randomized, double blind, placebo-controlled study
Citalopram in patients with fibromyalgia - a randomized, double blind, placebo-controlled study
复制标题
DOI：
10.1053/eujp.1999.0148
复制
发表时间：
2000-01-01
期刊：
影响因子：
--
通讯作者：
von Knorring, L
中科院分区：
文献类型：
--
作者：
Anderberg, UM;Marteinsdottir, I;von Knorring, L
在一项随机、双盲、安慰剂对照、为期 4 个月的试验中，研究人员对选择性 5-羟色胺再摄取抑制剂西酞普兰的作用进行了研究，试验对象是符合美国风湿病学会标准的纤维肌痛综合征 (FMS) 患者。西酞普兰的剂量在每天 20-40 mg 之间变化。 40 名女性患者参与其中，其中西酞普兰组 21 名，安慰剂组 19 名。使用视觉模拟量表（VAS）、蒙哥马利阿斯伯格抑郁量表（MADRS）和纤维炎影响问卷（FIQ）对疼痛、抑郁症状和身体功能进行评估。在总体改善判断中，无论是在意向治疗（ITT）分析还是在更完整的分析中，西酞普兰组和安慰剂组之间在疼痛或健康方面没有发现显着变化。然而，在完成者中，与安慰剂组 (22.2%) 相比，西酞普兰组 (52.9%) 的患者在健康方面有更多的改善。此外，结果表明，与基线相比，治疗 2 个月后，西酞普兰治疗对 VAS 疼痛有显着影响。然而4个月后，效果就减弱了。通过 FIQ 测量，在试验结束时可以看到疼痛等级存在显着差异。通过 MADRS 测量的抑郁症状在治疗 1 个月后就已经出现了显着影响，并且在试验结束时进一步增加，同时还发现了各组之间的显着差异。 (C) 2000 年国际疼痛研究协会欧洲分会联合会。
The effect of the selective serotonin reuptake inhibitor citalopram was studied in a randomized, double-blind, placebo-controlled, 4-month trial in patients with the fibromyalgia syndrome (FMS) who all fulfilled the American College of Rheumatology criteria. The citalopram doses varied between 20-40 mg daily. Forty female patients, 21 patients in the citalopram and 19 in the placebo group, participated. Assessment of pain, depressive symptoms and physical functioning were made using Visual Analogue Scales (VAS), the Montgomery Asberg Depression Rating Scale (MADRS) and the Fibrositis Impact Questionnaire (FIQ).In the global judgement of improvement, no significant changes were found between the citalopram and placebo groups as concerns pain or well-being, either in the Intention to Treat (ITT) analysis or in the completer analysis. However, among the completers, it was a tendency that more patients in the citalopram group (52.9%) were improved as compared to the placebo group (22.2%) concerning well-being.Furthermore, the results indicated that treatment with citalopram had a significant effect on pain on the VAS after 2 months of treatment compared to baseline. After 4 months, however, the effect had diminished. Measured with the FIQ, significant differences in the pain ratings were seen at the end of the trial.Significant effects on the depressive symptomatology measured by means of the MADRS were seen already after 1 month of treatment and were increasing further at the end of the trial, when a significant difference between the groups was also found. (C) 2000 European Federation of Chapters of the International Association for the Study of Pain.